|
Re: circulating tumor cells as a surrogate for response to treatment
If adequate tumor sample was readily available at every step of treatment in every case, and if cell tests could check for benefit of all available therapies, there would be less need for genomics/marker tests like above. The reality is, there is benefit to be had from both avenues whether used alone or in combination. The goal of the original post was not to propose superiority..just monitoring an additional tool in the toolbox.
|